Virginia Catalyst

Icarus Medical Innovations specializes in the design and manufacture of custom knee braces to treat osteoarthritis.

AgroSpheres develops novel technologies that aim to set a new standard for bio-based delivery of active ingredients. It uses a unique platform technology for crop protection solutions and other industrial applications. The company is an encapsulation and delivery technology that dramatically enhances the performance of a broad range of crop protection products including fungicides, insecticides, and herbicides. AgroSpheres was founded in 2016 and is based in Charlottesville, Virginia.

Tympanogen develops novel materials to improve treatment outcomes and decrease healthcare costs for otolaryngologists and their patients. Its flagship product, Perf-Fix, is the first gel patch for nonsurgical eardrum repair.

ReAlta Life Sciences is a clinical-stage biotech company dedicated to harnessing the power of the immune system to address life-threatening rare diseases. The company’s EPICC peptides are based on research into the human astrovirus, HAstV-1, which causes a non-inflammatory, self-limiting gastroenteritis unique among viruses by inhibiting components of the innate immune system. ReAlta’s therapeutic peptides leverage these virus-derived mechanisms to rebalance complement and inflammatory processes in the body. The company’s pipeline is led by RLS-0071, which has been granted Orphan Drug Designation by the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of hypoxic ischemic encephalopathy (HIE) in neonates. The company launched in 2018 and is located in Norfolk, Virginia.

Contraline is developing the first long-lasting, non-hormonal, reversible contraceptive for men

Ceres Nanosciences Inc. (“Ceres”) is a privately held life sciences company engaged in the research, development, and commercialization of innovative sample preparation products, based on its proprietary Nanotrap® technology, which captures, enriches and preserves analytes/biomarkers. Early detection of biomarkers, in particular those of low abundance, is key to the diagnosis and treatment of diseases such as cancer, cardiac, and infectious diseases, resulting in improved patient benefit and reduced health care costs. Ceres has a broad product pipeline of advanced sample collection technologies and diagnostics, funded through federal agency grants and industry collaboration funding. Ceres’ lead product in development is a direct antigen test for the diagnosis of Lyme disease, which will be available commercially in 2015.

Serpin Pharma is a privately held, development stage biotech company with research facilities in Northern Virginia, USA. We are developing a family of first in class anti-inflammatory and immune modulating peptides with potential application in inflammatory, autoimmune and infectious diseases.

VoltMed is a medical device company. They commit to helping cancer patients through the commercialization of the inspire platform. The platform provides unique benefits in destroying aberrant tissue. Inspire is based on evidence-based research.

Propagenix is a healthcare technology platform developer that aims to provide individualized diagnostics and cell therapies to improve human health. The company's systems are used in advanced therapies in development to differentiate primary epithelial adult stem cells for use in tissue models for drug discovery and toxicology screening, allowing medical professionals to address the acute shortage of transplantable organs that require mature, functional epithelial tissues such as skin, airways, and kidneys.

Sanyal Biotechnology is a contract research organization that specializes in pre-clinical small animal model screening of drugs. The biotech was built to serve the needs of clients who seek a more physiologically relevant small animal model for their preclinical research into liver disease and other comorbidities resulting from the metabolic syndrome. It has developed a proprietary isogenic mouse model, the DIAMONDᵀᴹ mouse, that develops NAFLD and NASH solely as a result of Western Diet. The progression of the pathology and physiological changes exactly parallel development of human liver disease due to metabolic syndrome.

BioTherapeutics Inc. (BTI) is a pre-clinical stage company developing novel small-molecule drugs to treat inflammation associated with autoimmune related disorders and type 2 diabetes (T2D)

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. The CellFX® System is the first commercial product to harness the distinctive advantages of NPS technology to treat a variety of applications for which an optimal solution remains unfulfilled. The initial commercial use of the CellFX System is to address a range of dermatologic conditions that share high demand among patients and practitioners for improved dermatologic outcomes. Designed as a multi-application platform, the CellFX System offers customer value with a utilization-based revenue model.